Blueprint Medicines Co. (NASDAQ:BPMC) Shares Acquired by Charles Schwab Investment Management Inc.

Charles Schwab Investment Management Inc. raised its holdings in shares of Blueprint Medicines Co. (NASDAQ:BPMC - Free Report) by 9.3% during the third quarter, according to its most recent filing with the SEC. The firm owned 597,232 shares of the biotechnology company's stock after purchasing an additional 50,736 shares during the period. Charles Schwab Investment Management Inc. owned 0.94% of Blueprint Medicines worth $55,244,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. American Century Companies Inc. boosted its stake in Blueprint Medicines by 4.2% in the second quarter. American Century Companies Inc. now owns 802,733 shares of the biotechnology company's stock valued at $86,519,000 after acquiring an additional 32,600 shares in the last quarter. Millennium Management LLC boosted its position in shares of Blueprint Medicines by 540.0% in the 2nd quarter. Millennium Management LLC now owns 627,626 shares of the biotechnology company's stock worth $67,646,000 after purchasing an additional 529,566 shares in the last quarter. Hood River Capital Management LLC grew its stake in Blueprint Medicines by 7.0% during the 2nd quarter. Hood River Capital Management LLC now owns 502,820 shares of the biotechnology company's stock worth $54,194,000 after buying an additional 32,694 shares during the last quarter. 1832 Asset Management L.P. increased its position in Blueprint Medicines by 200,159.4% during the 2nd quarter. 1832 Asset Management L.P. now owns 502,651 shares of the biotechnology company's stock valued at $54,176,000 after buying an additional 502,400 shares in the last quarter. Finally, Point72 Asset Management L.P. raised its stake in Blueprint Medicines by 79.3% in the second quarter. Point72 Asset Management L.P. now owns 501,581 shares of the biotechnology company's stock valued at $54,060,000 after buying an additional 221,813 shares during the last quarter.

Analyst Upgrades and Downgrades

Several equities analysts have recently issued reports on BPMC shares. Needham & Company LLC restated a "buy" rating and set a $135.00 price objective on shares of Blueprint Medicines in a report on Friday, November 15th. HC Wainwright restated a "buy" rating and set a $135.00 price target on shares of Blueprint Medicines in a research note on Friday, November 15th. StockNews.com upgraded shares of Blueprint Medicines from a "sell" rating to a "hold" rating in a research note on Friday, November 8th. UBS Group assumed coverage on Blueprint Medicines in a research report on Thursday, October 24th. They issued a "neutral" rating and a $88.00 target price on the stock. Finally, JPMorgan Chase & Co. initiated coverage on Blueprint Medicines in a research report on Thursday, November 14th. They set an "overweight" rating and a $126.00 price target for the company. One research analyst has rated the stock with a sell rating, seven have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average price target of $122.11.

Insider Buying and Selling at Blueprint Medicines

In other Blueprint Medicines news, insider Fouad Namouni sold 3,633 shares of Blueprint Medicines stock in a transaction on Thursday, October 3rd. The shares were sold at an average price of $89.32, for a total transaction of $324,499.56. Following the sale, the insider now owns 69,070 shares of the company's stock, valued at $6,169,332.40. The trade was a 5.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Insiders own 4.21% of the company's stock.

Blueprint Medicines Price Performance

Shares of Blueprint Medicines stock traded up $1.28 on Friday, reaching $96.38. The company's stock had a trading volume of 338,237 shares, compared to its average volume of 632,778. Blueprint Medicines Co. has a 52-week low of $68.28 and a 52-week high of $121.90. The company has a market capitalization of $6.12 billion, a P/E ratio of -45.68 and a beta of 0.59. The company has a quick ratio of 3.27, a current ratio of 3.32 and a debt-to-equity ratio of 1.09. The stock has a 50-day moving average price of $90.97 and a 200-day moving average price of $98.10.

Blueprint Medicines (NASDAQ:BPMC - Get Free Report) last posted its quarterly earnings data on Wednesday, October 30th. The biotechnology company reported ($0.89) earnings per share for the quarter, topping analysts' consensus estimates of ($0.97) by $0.08. The company had revenue of $128.20 million during the quarter, compared to analysts' expectations of $127.56 million. Blueprint Medicines had a negative net margin of 29.48% and a negative return on equity of 112.30%. The firm's revenue for the quarter was up 126.5% on a year-over-year basis. During the same period in the prior year, the business posted ($2.20) earnings per share. Analysts expect that Blueprint Medicines Co. will post -3.68 EPS for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.